One of Nanologica’s patent applications has today become public. Through the patent, Nanologica is seeking to strengthen and expand its technology platform by adding inhalation, among other, as administration route.
The technology is in an early phase and is believed to be able to overcome some of the challenges surrounding administration of drugs through inhalation.
”Inhalation interests us for several reasons. We see great potential in the reformulation of approved substances for finding more effective treatments for various lung diseases, today difficult to treat. Several molecules and indications could be of interest and through local administration in the lung there is a possibility of lowering the systemic effects with potentially lower side effects as a result”, states Andreas Bhagwani, CEO of Nanologica,
Inhalation is one of several administration routes being explored within Nanologica’s technology platform and the patent application is a PCT application.
For additional information, please contact:
Andreas Bhagwani, CEO Nanologica
Tel: +46 70 316 17 02 or e-mail: andreas.bhagwani@nanologica.com
ABOUT NANOLOGICA AB (publ)
Nanologica develops nanoporous silica for applications in life science. The company focuses on twob usiness areas: drug delivery and chromatography, a technology used for the separation and purification of products on the market and in development. Nanologica’s core competence is to apply its unique know-how in the field of material science for developing nanoporous silica particles with unique characteristics. Based in Södertälje, Sweden, Nanologica has 16 employees from eight nationalities of which eight are PhDs. For more information, please visit www.nanologica.com.